#USA #San Diego #Advisory Board #Circular Genomics #circRNA

Circular Genomics Strengthens Its Leadership with New Commercial Advisory Board

Circular Genomics, Inc., recognized as a frontrunner in the circular RNA (circRNA) biomarker domain targeting precision neurology and psychiatry, recently announced the establishment of its Commercial Advisory Board (CAB) comprised of notable industry veterans. This strategic move aims to propel the company’s initiatives to enhance the availability of circRNA-based precision medicine tools designed to benefit patients grappling with severe chronic conditions, including Alzheimer's disease and various neurological and psychiatric ailments.

Expert Guidance for Precision Medicine Transformation
The newly inaugurated CAB will collaborate closely with Circular Genomics' executive leadership team, offering invaluable insights and strategies necessary for advancing the company’s diverse pipeline of circRNA biomarker programs. By leveraging the profound expertise brought by the members of the CAB, Circular Genomics intends to translate groundbreaking scientific advances into meaningful health outcomes for patients.

Sami Shihabi, the Chief Commercial Officer of Circular Genomics, expressed enthusiasm and respect towards the board members, stating, "We are thrilled and honored to welcome such industry leaders to our Commercial Advisory Board as we advance and broaden our pipeline of precision neurology and psychiatry diagnostics. These esteemed members bring deep expertise in market access and commercial execution - key drivers as we aim to transform patient care through our pioneering circRNA platform. We are confident they will provide invaluable strategic guidance as we expand our go-to-market plans."

Meet the Inaugural Members of the CAB
The CAB features a compilation of distinguished leaders including Andrew Lechleiter, Laura Viaches, Melissa Reilly, and James Grana, each bringing extensive experience from various sectors within healthcare.

• - Andrew Lechleiter is a seasoned executive with more than 20 years in commercial operations, marketing, and general management across U.S. and global markets. Currently serving as the CEO of Poplar Grove Investors, he also has a rich history at Eli Lilly and Abbott Vascular, where he was pivotal in launching innovative treatments for Alzheimer’s disease.

• - Laura Viaches has spent over two decades in the pharmaceutical industry, including significant leadership roles at Eli Lilly. She currently leads Endeavor Pharma Solutions, focusing on market access strategies for Alzheimer’s Disease. Her deep knowledge spans a multitude of aspects from payer marketing to field reimbursement strategies.

• - Melissa Reilly is notable in behavioral healthcare, having accrued over a decade of experience in scaling healthcare technology firms. As the former Chief Growth Officer at Evernorth Behavioral Health, she emphasizes expanding access to mental health solutions, and now leads STLTH CNSLTNG, an advisory practice concentrating on healthcare innovation.

• - James Grana is recognized for his extensive background in Value-Based Care. With leadership roles in various prominent healthcare organizations, he has been influential in driving innovations through analytics and partnerships. His previous military service adds a unique perspective to his professional accomplishments.

Future Aspirations for Circular Genomics
With aspirations to enhance the CAB by including other notable leaders from the field of commercial operations and market development, Circular Genomics is committed to enriching its mission: delivering actionable insights for the diagnosis, monitoring, and treatment of neurological and psychiatric conditions. The company is firmly rooted in the conviction that their pioneering circular RNA platform will redefine the standards of care across major psychiatric and neurological diseases, heralding an era of rapid treatment effectiveness that is measured not in months, but within days to weeks.

About Circular Genomics
Circular Genomics is at the forefront of developing circular RNA-based precision medicine tools for the fields of neurology and psychiatry. By utilizing exclusive technologies in circular RNA, the company aims to revolutionize treatment approaches for disorders such as major depressive disorder and more. Their ongoing commitment is to enable more efficient and effective treatment protocols tailored to individual patient needs. For more information on their innovative approaches, explore their offerings at www.circulargenomics.com.

Circular Genomics' ambitious plans through its newly formed CAB signify a bold step towards refining patient care in the complex landscape of neurological and psychiatric health.